Clinical Trial Update: Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating coagulation factor VIIa variant marzeptacog alfa (activated) in adults with hemophilia A or B with inhibitors; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Marzeptacog Alfa (Activated) (Marzeptacog alfa activated)

Snippet

Sponsor: Catalyst Biosciences | Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 2 | Status: COMPLETED | Results posted: 2021-09-23